Details
Stereochemistry | ACHIRAL |
Molecular Formula | 2O.Ti |
Molecular Weight | 79.866 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O--].[O--].[Ti+4]
InChI
InChIKey=SOQBVABWOPYFQZ-UHFFFAOYSA-N
InChI=1S/2O.Ti/q2*-2;+4
Molecular Formula | O |
Molecular Weight | 15.9994 |
Charge | -2 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | Ti |
Molecular Weight | 47.867 |
Charge | 4 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_ClinPharmR.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18503414
Curator's Comment: description was created based on several sources, including
https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_ClinPharmR.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18503414
Titanium dioxide, also known as titanium(IV) oxide or titania, is the naturally occurring oxide of titanium, chemical formula TiO
2. When used as a pigment, it is called titanium white, Pigment White 6 (PW6), or CI 77891. Generally it is sourced from ilmenite, rutile and anatase. It has a wide range of applications, from paint to sunscreen to food coloring. When used as a food coloring, it has E number E171. World production in 2014 exceeded 9 million metric tons. Titanium dioxide has excellent ultraviolet (UV) resistant qualities and acts as a UV absorbent. In the pharmaceutical industry, titanium dioxide is used in most sunscreens to block UVA and UVB rays, similar to zinc oxide. It is also commonly used as pigment for pharmaceutical products such as gelatin capsules, tablet coatings and syrups. In the cosmetics industry, it is used in toothpaste, lipsticks, creams, ointments and powders. It can be used as an opacifier to make pigments opaque. The FDA has approved the safety of titanium dioxide for use as a colorant in food, drugs and cosmetics, including sunscreens. However, controversy exists as to the safety of titanium dioxide nanoparticles used in the cosmetics industry, for example in sunscreens. Titanium and zinc oxides may be made into the nanoparticle size (0.2-100 nanometers) to reduce the white appearance when applied topically, but retain the UV blocking properties. Recent studies suggest titanium dioxide nanoparticles may be toxic, although further research is needed.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18503414
Curator's Comment: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/022009s000_ClinPharmR.pdf
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: ultraviolet induced damage Sources: https://www.ncbi.nlm.nih.gov/pubmed/18503257 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Preventing | ANTHELIOS 40 Approved UseUnknown Launch Date2008 |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Titanium, chromium and cobalt ions modulate the release of bone-associated cytokines by human monocytes/macrophages in vitro. | 1996 Dec |
|
Matrix metalloproteinases MMP-2, -9 and tissue inhibitors TIMP-1, -2 expression and secretion by primary human osteoblast cells in response to titanium, zirconia, and alumina ceramics. | 2004 Jan 1 |
|
Molecular and biomechanical characterization of mineralized tissue by dental pulp cells on titanium. | 2005 Jun |
|
Chemokine gene activation in human bone marrow-derived osteoblasts following exposure to particulate wear debris. | 2006 Apr |
|
Upregulation of LITAF mRNA expression upon exposure to TiAlV and polyethylene wear particles in THP-1 macrophages. | 2007 Apr |
|
Reconsideration of serum Ti(IV) transport: albumin and transferrin trafficking of Ti(IV) and its complexes. | 2008 Feb 20 |
|
Alumina ceramic particles, in comparison with titanium particles, hardly affect the expression of RANK-, TNF-alpha-, and OPG-mRNA in the THP-1 human monocytic cell line. | 2009 Jun |
|
Influence of metals on cytokines production in connection with successful implantation therapy in dentistry. | 2010 |
|
Engineered nanomaterials cause cytotoxicity and activation on mouse antigen presenting cells. | 2010 Jan 12 |
|
Titanium ion induces necrosis and sensitivity to lipopolysaccharide in gingival epithelial-like cells. | 2010 Oct |
|
The effect of TiO(2) and Ag nanoparticles on reproduction and development of Drosophila melanogaster and CD-1 mice. | 2011 Dec 15 |
|
Toll-like receptors and their adaptors are regulated in macrophages after phagocytosis of lipopolysaccharide-coated titanium particles. | 2011 Jul |
|
Cellular oxidative damage of HEK293T cells induced by combination of CdCl(2) and nano-TiO (2). | 2011 Jun |
|
Particle stimulation dephosphorylates glutathione S-transferase π1 of epithelial cells. | 2011 Jun 18 |
|
Titanium oxide shell coatings decrease the cytotoxicity of ZnO nanoparticles. | 2011 Mar 21 |
|
Safety evaluation of sunscreen formulations containing titanium dioxide and zinc oxide nanoparticles in UVB sunburned skin: an in vitro and in vivo study. | 2011 Sep |
|
Gene expression of zebrafish embryos exposed to titanium dioxide nanoparticles and hydroxylated fullerenes. | 2011 Sep |
|
Ovarian dysfunction and gene-expressed characteristics of female mice caused by long-term exposure to titanium dioxide nanoparticles. | 2012 Dec |
|
Genetic variation influences immune responses in sensitive rats following exposure to TiO2 nanoparticles. | 2014 Dec 4 |
|
Titanium dioxide nanoparticles promote arrhythmias via a direct interaction with rat cardiac tissue. | 2014 Dec 9 |
|
Genotoxicity of silver and titanium dioxide nanoparticles in bone marrow cells of rats in vivo. | 2014 Jan 6 |
|
Zinc oxide nanoparticles induce migration and adhesion of monocytes to endothelial cells and accelerate foam cell formation. | 2014 Jul 1 |
|
Normalization of nano-sized TiO2-induced clastogenicity, genotoxicity and mutagenicity by chlorophyllin administration in mice brain, liver, and bone marrow cells. | 2014 Nov |
|
Sheet-type titania, but not P25, induced paraptosis accompanying apoptosis in murine alveolar macrophage cells. | 2014 Oct 1 |
|
Effects of titanium dioxide nanoparticles on lead bioconcentration and toxicity on thyroid endocrine system and neuronal development in zebrafish larvae. | 2015 Apr |
|
Oxidative and pro-inflammatory effects of cobalt and titanium oxide nanoparticles on aortic and venous endothelial cells. | 2015 Apr |
|
Release of titanium ions from an implant surface and their effect on cytokine production related to alveolar bone resorption. | 2015 Jan 2 |
|
Titanium nanoparticle inhalation induces renal fibrosis in mice via an oxidative stress upregulated transforming growth factor-β pathway. | 2015 Mar 16 |
|
TiO2 nanoparticle-induced neurotoxicity may be involved in dysfunction of glutamate metabolism and its receptor expression in mice. | 2016 Jun |
Sample Use Guides
Apply evenly 15 minutes before sun exposure. Reapply as needed or after towel drying, swimming, or perspiring. Children under 6 months of age, ask a doctor.
Route of Administration:
Topical
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/18503414
For the in vitro studies, the stratum corneum side of the skin was in contact with either the aqueous or oily commercial dispersion of microfine TiO2 (150 μl/cm^2). The dermis side was placed onto a tissue of cellulose soaked with isotonic phosphate buffered saline (PBS) of pH 7.4. Twenty-four hours after application of the dispersion, the PBS was removed from the skin with a dry paper towel. For the in vivo studies, 2 μl cm−2 of the commercial dispersions and the different formulations were applied onto the ventral side of the forearm of a healthy female volunteer. After 45 min, any dispersion or formulation that had not penetrated the skin was also removed with a paper towel. All penetration tests were performed in triplicate.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:04:03 GMT 2025
by
admin
on
Mon Mar 31 18:04:03 GMT 2025
|
Record UNII |
15FIX9V2JP
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
CODEX ALIMENTARIUS (GSFA) |
INS-171
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 178.3297
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
NCI_THESAURUS |
C461
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
DSLD |
1166 (Number of products:1)
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 38
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
199204
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 575
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
JECFA EVALUATION |
INS-171
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 352.20
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 176.170
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 175.210
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/05/262
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
EPA PESTICIDE CODE |
NOT YET ASSIGNED
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 576
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
CFR |
21 CFR 352.10
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
FDA ORPHAN DRUG |
142401
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
||
|
Food Contact Sustance Notif, (FCN No.) |
FCN NO. 577
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB12611MIG
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
869
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
C61975
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
C009495
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
DB09536
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
DTXSID3021352
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
1667585
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
4237
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
1317-80-2
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
ALTERNATIVE | |||
|
162651
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
46748
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
13463-67-7
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
38323
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
15FIX9V2JP
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
TITANIUM DIOXIDE
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
32234
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
134438
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
236-675-5
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
15FIX9V2JP
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
1344-29-2
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
ALTERNATIVE | |||
|
m10898
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | Merck Index | ||
|
100000092217
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
CHEMBL1201136
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY | |||
|
215-282-2
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
ALTERNATIVE | |||
|
15204
Created by
admin on Mon Mar 31 18:04:03 GMT 2025 , Edited by admin on Mon Mar 31 18:04:03 GMT 2025
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
|